Trial reportContemporary clinical trials2013
Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans.
Trial report in Contemporary clinical trials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04284436 (Study in Parkinson Disease of Exercise Phase 3 Clinical Trial), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3
Who cites it
25 citing papers in PubMed.
- Effects of 6 months of endurance exercise on motor function, exercise capacity, and autonomic function based on presence of autonomic dysfunction in individuals with early Parkinson's disease.Journal of Parkinson's disease · 2025Trial
- Exercising with a robotic exoskeleton can improve memory and gait in people with Parkinson's disease by facilitating progressive exercise intensity.Scientific reports · 2024Trial
- Using gait robotics to improve symptoms of Parkinson's disease: an open-label, pilot randomized controlled trial.European journal of physical and rehabilitation medicine · 2022Trial
- High intensity aerobic exercise improves bimanual coordination of grasping forces in Parkinson's disease.Parkinsonism & related disorders · 2021Trial
- Trial
- Effectiveness of Rotigotine plus intensive and goal-based rehabilitation versus Rotigotine alone in "de-novo" Parkinsonian subjects: a randomized controlled trial with 18-month follow-up.Journal of neurology · 2018Trial
- Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial.JAMA neurology · 2018Trial
- Factors Associated With Ambulatory Activity in De Novo Parkinson Disease.Journal of neurologic physical therapy : JNPT · 2017Trial
- Lactate dynamics in Parkinson's disease: striatal circuit vulnerability, biomarker potential, and therapeutic windows.Molecular medicine (Cambridge, Mass.) · 2026Review
- Impact of an intensive outpatient rehabilitation on non-motor patients' reported outcomes in PD: the INTENSO study.NPJ Parkinson's disease · 2025Article
- BetaBiomedicines · 2024Article
- Chronotropic Incompetence During Exercise Testing as a Marker of Autonomic Dysfunction in Individuals with Early Parkinson's Disease.Journal of Parkinson's disease · 2024Article
- REM Behavior Disorder: Implications for PD Therapeutics.Current neurology and neuroscience reports · 2023Review
- Molecular mechanisms underlying the neuroprotection of environmental enrichment in Parkinson's disease.Neural regeneration research · 2023Review
- Efficacy of exercises in early-stage Parkinson's disease (PARK-EASE trial): single-blind, randomised, controlled trial.BMJ neurology open · 2023Article
- Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.Trials · 2022Article
- Clinical Trial Highlights - Aerobic Exercise for Parkinson's Disease.Journal of Parkinson's disease · 2022Article
- Does MDS-UPDRS Provide Greater Sensitivity to Mild Disease than UPDRS in De Novo Parkinson's Disease?Movement disorders clinical practice · 2021Article
- Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.Movement disorders : official journal of the Movement Disorder Society · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
A burgeoning literature suggests that exercise has a therapeutic benefit in persons with Parkinson disease (PD) and in animal models of PD, especially when animals exercise at high intensity. If exercise is to be prescribed as "first-line" or "add-on" therapy in patients with PD, we must demonstrate its efficacy and dose-response effects through testing phases similar to those used in the testing of pharmacologic agents. The SPARX Trial is a multicenter, randomized, controlled, single-blinded, Phase II study that we designed to test the feasibility of using high-intensity exercise to modify symptoms of PD and to simultaneously test the nonfutility of achieving a prespecified change in patients' motor scores on the Unified Parkinson Disease Rating Scale (UPDRS). The trial began in May 2102 and is in the process of screening, enrolling, and randomly assigning 126 patients with early-stage PD to 1 of 3 groups: usual care (wait-listed controls), moderate-intensity exercise (4 days/week at 60%-65% maximal heart rate [HRmax]), or high-intensity exercise (4 days/week at 80%-85% HRmax). At 6-month follow-up, the trial is randomly reassigning usual care participants to a moderate-intensity or high-intensity exercise group for the remaining 6 months. The goals of the Phase II trial are to determine if participants can exercise at moderate and high intensities; to determine if either exercise yields benefits consistent with meaningful clinical change (nonfutility); and to document safety and attrition. The advantage of using a non-futility approach allows us to efficiently determine if moderate- or high-intensity exercise warrants further large-scale investigation in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.